Clinical Trials Logo

Filter by:
NCT ID: NCT01599351 Completed - Clinical trials for Exposure to Ionizing Radiation

Radiation Exposure During Endoscopic Retrograde Cholangiopancreatography Between Prone and Left Lateral Decubitus

Start date: July 2009
Phase: Phase 4
Study type: Interventional

The objective of this study is to evaluate the radiation dose to patient at two positions (prone and left lateral) and to medical staff during Endoscopic retrograde cholangiopancreatography (ERCP) procedure using dose area product (DAP) meter and thermoluminescent dosimeter (TLD). Data were recorded on 20 patients at prone position and 20 patients at left lateral position.

NCT ID: NCT01598012 Completed - Clinical trials for Primary Dysmenorrhea

The Efficacy of Ayurved Siriraj Prasaplai for Treatment Primary Dysmenorrhea

Start date: December 2011
Phase: Phase 4
Study type: Interventional

Ayurved Siriraj Prasaplai is a Thai traditional herbal drug for pain treatment. Mostly it was used for antipain during menstruation or dysmenorrhea. This drug has been described by alternative medical doctor for treatment of primary dysmenorrhea for more than 10 years and showed clinical satisfied response. From review about this agent, it does not have clinical trial to prove its efficacy. So the author produce this research to study in efficacy of Ayurved Siriraj Prasaplai.

NCT ID: NCT01597999 Recruiting - Clinical trials for Invasive Breast Cancer

Benefits of Breast MRI for Predicting of Histopathologic Cell Type of Small Breast Cancer

Start date: February 2011
Phase: Phase 4
Study type: Interventional

This study examines the additional benefits of magnetic resonance imaging (MRI) with Gadovist in early breast cancer with poor prognostic features.

NCT ID: NCT01597973 Completed - Pneumonia Clinical Trials

Trial for the Treatment of Extensively Drug-Resistant Gram-negative Bacilli (OVERCOME)

Start date: October 6, 2012
Phase: Phase 3
Study type: Interventional

Approximately 444 subjects who are greater than or equal to 18 to 95 years of age, are non-pregnant, and are in the inpatient setting of one of the study sites will be evaluated to treatment efficacy. Analysis will include subjects with bloodstream infection (BSI) or pneumonia due to at least one of the following gram-negative bacilli organisms: Acinetobacter baumannii, Klebsiella spp, Escherichia coli, Enterobacter spp. and/or Pseudomonas aeruginosa that demonstrates in vitro non-susceptibility defined as extensively drug-resistant Gram-negative bacilli (XDR-GNB) which includes XDR-AB, XDR-PA and CRE. If a subject has both BSI and pneumonia at the time of study enrollment, they will be included as a subject with pneumonia. Objectives: Primary: •Determine whether the treatment regimen of Colistimethate sodium (colistin) combined with a carbapenem (imipenem or meropenem) is associated with a decreased risk for mortality compared to colistin alone for subjects with bloodstream infection (BSI) and/or pneumonia due to XDR-GNB. Secondary: •Determine what treatment regimen (colistin monotherapy or colistin combined with a carbapenem (imipenem or meropenem) is more likely to reduce the emergence of colistin resistance among XDR-GNB isolates during therapy.

NCT ID: NCT01597765 Completed - Thalassemia Clinical Trials

Effect of Antioxidant Cocktail in Beta-thalassemia/Hb E Patients

Start date: June 2009
Phase: N/A
Study type: Interventional

The purpose of this study is to determine the efficacy of antioxidant cocktails on the alleviation of oxidative stress and iron overload in beta-thalassemia/Hb E patients.

NCT ID: NCT01597687 Completed - Pertussis Clinical Trials

Pertussis Infection in Adolescents and Adults With Prolonged Cough

Start date: June 20, 2012
Phase: N/A
Study type: Interventional

This study aims to determine the burden of pertussis infection among adolescents and adults with prolonged cough in four Asian countries, namely Malaysia, Philippines, Taiwan and Thailand. This study also aims to assess the health economic (HE) impact of pertussis.

NCT ID: NCT01594931 Completed - Clinical trials for Plasmodium Falciparum Malaria

Phase II Dose-ranging Study of Pyronaridine/Artesunate in Adults Patients With Plasmodium Falciparum Malaria

Start date: July 2005
Phase: Phase 2
Study type: Interventional

The primary trial objective is to determine the clinically effective dose of orally administered pyronaridine/artesunate (Pyramax®, PA) with a 3:1 ratio to treat adults with acute, symptomatic, uncomplicated P. falciparum malaria in South East Asia and Africa. Secondary trial objectives are to determine the safety of once-daily dosing for 3 days of PA and to explore possible ethnic differences in safety or efficacy.

NCT ID: NCT01593566 Completed - Clinical trials for Analgesia After ACL Reconstruction

Femoral Nerve Block for Analgesia After Anterior Cruciate Ligament Reconstruction

FNB for ACLR
Start date: April 2011
Phase: Phase 4
Study type: Interventional

Femoral nerve block using 0.25% bupivacaine or 0.5% bupivacaine provides a longer time for analgesia after Anterior Cruciate Ligament (ACL) reconstruction.

NCT ID: NCT01593254 Completed - Clinical trials for Chronic Phase Chronic Myeloid Leukemia

Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib

DASCERN
Start date: September 12, 2012
Phase: Phase 2
Study type: Interventional

The purpose of this study is to test the hypothesis that patients with CML who have not achieved optimal response after 3 months of treatment with imatinib will have a better response by switching to dasatinib compared to staying on their original imatinib regimen.

NCT ID: NCT01591122 Completed - Prostate Cancer Clinical Trials

Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer

Start date: March 27, 2012
Phase: Phase 3
Study type: Interventional

The purpose of this study is to demonstrate the safety and effectiveness of abiraterone acetate when co-administered with prednisone in patients with chemo-naive metastatic castration resistant prostate Cancer (mCRPC).